- Dogwood Therapeutics (DWTX) has secured a **global license** to develop and commercialize **SP sixteen**, a first-in-class LRP one agonist, as a complementary treatment for chemotherapy-induced peripheral neuropathy (CIPN).  **[1818844_2160767_1]** 
- The SP sixteen acquisition is an **all-stock transaction** with **no royalty obligations** or future development milestones, and its **Phase 1b clinical research** is **fully funded by the National Cancer Institute (NCI)**.  **[1818844_2160767_1]** **[1818844_2160767_7]** **[1818844_2160767_8]** 
- Dogwood plans to file an **IND for SP sixteen in Q4 2025** and expects to commence patient dosing in **H1 2026**.  **[1818844_2160767_3]** **[1818844_2160767_7]** 
- The company also provided an update on its lead compound, Halneuron, reporting **82 patients enrolled** in its Phase 2b study for CIPN, with an interim analysis anticipated by **December (Q4 2025)**.  **[1818844_2160767_2]**

Dogwood Therapeutics Licenses SP Sixteen and Provides Clinical Updates

- Dogwood Therapeutics is progressing its **Halneuron® Na 1.7** program for Chemotherapy-Induced Neuropathic Pain (CINP), with **80 patients randomized** in the ongoing Phase 2b study out of a target enrollment of **200 patients**.  **[1818844_2160635:1]**  An **interim data readout** for this study is projected for **Q4 2025**.  **[1818844_2160635:1]** **[1818844_2160635:8]** 
- The company has secured a **royalty-free, global license** for **Serpin Pharma's IV formulation of SP16**, a clinical-stage candidate for neuropathy and nerve damage.  **[1818844_2160635:2]**  The **Phase 1b trial for SP16 is fully funded by the National Cancer Institute (NCI)**, with an **IND filing planned for Q4 2025** and **patient enrollment starting in 1H 2026**.  **[1818844_2160635:2]** **[1818844_2160635:8]** 
- This new license expands Dogwood's pipeline, with SP16 offering potential for **nerve repair and prevention** that could synergistically complement Halneuron® in treating CINP.  **[1818844_2160635:3]** **[1818844_2160635:7]** 
- Key upcoming milestones for **Q4 2025** include filing new synthetic Halneuron® IP, recruiting 100 patients in the Halneuron® Phase 2b study, the Halneuron® Phase 2b interim data readout, and filing the SP16 IND.  **[1818844_2160635:8]**

Dogwood Therapeutics Provides Update on Halneuron® and SP16 Clinical Programs

- Dogwood Therapeutics, Inc. has secured an **exclusive worldwide, royalty-free license** to develop and commercialize **SP16** as a treatment for cancer-related pain, including chemotherapy-induced neuropathy (CIPN).  **[1818844_0001104659-25-094109_dwtx-20250929xex99d1.htm:0]** 
- The transaction was structured as an **all-stock deal**, with Serpin Pharma and its affiliates receiving **382,034 shares of common stock and 179.1878 shares of non-voting convertible preferred stock**, which collectively represent **7.31% of Dogwood's common stock on a fully diluted basis**.  **[1818844_0001104659-25-094109_dwtx-20250929xex99d1.htm:1]** **[1818844_0001104659-25-094109_dwtx-20250929xex99d2.htm:2]** 
- The **National Cancer Institute (NCI) will fully fund the Phase 1b CIPN study for SP16 IV**, with patient enrollment projected to begin in the **first half of 2026**.  **[1818844_0001104659-25-094109_dwtx-20250929xex99d1.htm:0]** **[1818844_0001104659-25-094109_dwtx-20250929xex99d2.htm:1]** **[1818844_0001104659-25-094109_dwtx-20250929x8k.htm:2]** 
- SP16, a first-in-class LRP1 agonist, is expected to **synergistically complement Halneuron®**, Dogwood's late-stage NaV1.7 inhibitor, in addressing CIPN.  **[1818844_0001104659-25-094109_dwtx-20250929xex99d1.htm:0]** **[1818844_0001104659-25-094109_dwtx-20250929xex99d2.htm:1]**